R I Calderón1, G E Velásquez2, M C Becerra3, Z Zhang4, C C Contreras5, R M Yataco5, J T Galea5, L W Lecca5, A L Kritski6, M B Murray7, C D Mitnick3. 1. Socios En Salud Sucursal Peru, Lima, Peru; Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil. 2. Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA; Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA. 3. Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA; Division of Global Health Equity, Brigham and Women's Hospital, Boston, Massachusetts, USA. 4. Division of Global Health Equity, Brigham and Women's Hospital, Boston, Massachusetts, USA. 5. Socios En Salud Sucursal Peru, Lima, Peru. 6. Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil. 7. Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA; Division of Global Health Equity, Brigham and Women's Hospital, Boston, Massachusetts, USA; Department of Epidemiology, Harvard T H Chan School of Public Health, Boston, Massachusetts, USA.
Abstract
BACKGROUND: Multidrug-resistant tuberculosis (MDR-TB) regimens often contain pyrazinamide (PZA) even if susceptibility to the drug has not been confirmed. This gap is due to the limited availability and reliability of PZA susceptibility testing. OBJECTIVES: To estimate the prevalence of PZA resistance using the Wayne assay among TB patients in Lima, Peru, to describe characteristics associated with PZA resistance and to compare the performance of Wayne with that of BACTEC™ MGIT™ 960. METHODS: PZA susceptibility using the Wayne assay was tested in patients diagnosed with culture-positive pulmonary TB from September 2009 to August 2012. Factors associated with PZA resistance were evaluated. We compared the performance of the Wayne assay to that of MGIT 960 in a convenience sample. RESULTS: The prevalence of PZA resistance was 6.6% (95%CI 5.8-7.5) among 3277 patients, and 47.7% (95%CI 42.7-52.6) among a subset of 405 MDR-TB patients. In multivariable analysis, MDR-TB (OR 86.0, 95%CI 54.0-136.9) and Latin American-Mediterranean lineage (OR 3.40, 95%CI 2.33-4.96) were associated with PZA resistance. The Wayne assay was in agreement with MGIT 960 in 83.9% of samples (κ 0.66, 95%CI 0.56-0.76). CONCLUSION: PZA resistance was detected using the Wayne assay in nearly half of MDR-TB patients in Lima. This test can inform the selection and composition of regimens, especially those dependent on additional resistance.
BACKGROUND:Multidrug-resistant tuberculosis (MDR-TB) regimens often contain pyrazinamide (PZA) even if susceptibility to the drug has not been confirmed. This gap is due to the limited availability and reliability of PZA susceptibility testing. OBJECTIVES: To estimate the prevalence of PZA resistance using the Wayne assay among TB patients in Lima, Peru, to describe characteristics associated with PZA resistance and to compare the performance of Wayne with that of BACTEC™ MGIT™ 960. METHODS:PZA susceptibility using the Wayne assay was tested in patients diagnosed with culture-positive pulmonary TB from September 2009 to August 2012. Factors associated with PZA resistance were evaluated. We compared the performance of the Wayne assay to that of MGIT 960 in a convenience sample. RESULTS: The prevalence of PZA resistance was 6.6% (95%CI 5.8-7.5) among 3277 patients, and 47.7% (95%CI 42.7-52.6) among a subset of 405 MDR-TB patients. In multivariable analysis, MDR-TB (OR 86.0, 95%CI 54.0-136.9) and Latin American-Mediterranean lineage (OR 3.40, 95%CI 2.33-4.96) were associated with PZA resistance. The Wayne assay was in agreement with MGIT 960 in 83.9% of samples (κ 0.66, 95%CI 0.56-0.76). CONCLUSION:PZA resistance was detected using the Wayne assay in nearly half of MDR-TB patients in Lima. This test can inform the selection and composition of regimens, especially those dependent on additional resistance.
Authors: Molly F Franke; Mercedes C Becerra; Dylan B Tierney; Michael L Rich; Cesar Bonilla; Jaime Bayona; Megan M McLaughlin; Carole D Mitnick Journal: Ann Am Thorac Soc Date: 2015-05
Authors: Jonathan L Zelner; Megan B Murray; Mercedes C Becerra; Jerome Galea; Leonid Lecca; Roger Calderon; Rosa Yataco; Carmen Contreras; Zibiao Zhang; Justin Manjourides; Bryan T Grenfell; Ted Cohen Journal: J Infect Dis Date: 2015-07-14 Impact factor: 5.226
Authors: Leila de Souza Fonseca; Anna Grazia Marsico; Gisele Betzler de Oliveira Vieira; Rafael da Silva Duarte; Maria Helena Féres Saad; Fernanda de Carvalho Queiroz Mello Journal: J Bras Pneumol Date: 2012 Sep-Oct Impact factor: 2.624
Authors: G P Morlock; J T Crawford; W R Butler; S E Brim; D Sikes; G H Mazurek; C L Woodley; R C Cooksey Journal: Antimicrob Agents Chemother Date: 2000-09 Impact factor: 5.191
Authors: J Domínguez; E C Boettger; D Cirillo; F Cobelens; K D Eisenach; S Gagneux; D Hillemann; R Horsburgh; B Molina-Moya; S Niemann; E Tortoli; A Whitelaw; C Lange Journal: Int J Tuberc Lung Dis Date: 2016-01 Impact factor: 2.373
Authors: Philip Supply; Caroline Allix; Sarah Lesjean; Mara Cardoso-Oelemann; Sabine Rüsch-Gerdes; Eve Willery; Evgueni Savine; Petra de Haas; Henk van Deutekom; Solvig Roring; Pablo Bifani; Natalia Kurepina; Barry Kreiswirth; Christophe Sola; Nalin Rastogi; Vincent Vatin; Maria Cristina Gutierrez; Maryse Fauville; Stefan Niemann; Robin Skuce; Kristin Kremer; Camille Locht; Dick van Soolingen Journal: J Clin Microbiol Date: 2006-09-27 Impact factor: 5.948
Authors: Pushpendra Singh; Clement Wesley; G P S Jadaun; Sunil Kumar Malonia; R Das; P Upadhyay; J Faujdar; P Sharma; P Gupta; Abhay Kumar Mishra; Kalpana Singh; D S Chauhan; V D Sharma; U D Gupta; K Venkatesan; V M Katoch Journal: J Clin Microbiol Date: 2006-11-08 Impact factor: 5.948
Authors: G CANETTI; S FROMAN; J GROSSET; P HAUDUROY; M LANGEROVA; H T MAHLER; G MEISSNER; D A MITCHISON; L SULA Journal: Bull World Health Organ Date: 1963 Impact factor: 9.408
Authors: Courtney M Yuen; Ekaterina V Kurbatova; Thelma Tupasi; Janice Campos Caoili; Martie Van Der Walt; Charlotte Kvasnovsky; Martin Yagui; Jaime Bayona; Carmen Contreras; Vaira Leimane; Julia Ershova; Laura E Via; HeeJin Kim; Somsak Akksilp; Boris Y Kazennyy; Grigory V Volchenkov; Ruwen Jou; Kai Kliiman; Olga V Demikhova; Irina A Vasilyeva; Tracy Dalton; J Peter Cegielski Journal: PLoS Med Date: 2015-12-29 Impact factor: 11.069
Authors: Sonya S Shin; Martin Yagui; Luis Ascencios; Gloria Yale; Carmen Suarez; Neyda Quispe; Cesar Bonilla; Joaquin Blaya; Allison Taylor; Carmen Contreras; Peter Cegielski Journal: Emerg Infect Dis Date: 2008-05 Impact factor: 6.883
Authors: Avika Dixit; Luca Freschi; Roger Vargas; Roger Calderon; James Sacchettini; Francis Drobniewski; Jerome T Galea; Carmen Contreras; Rosa Yataco; Zibiao Zhang; Leonid Lecca; Sergios-Orestis Kolokotronis; Barun Mathema; Maha R Farhat Journal: Sci Rep Date: 2019-04-03 Impact factor: 4.379
Authors: M J Nasiri; F Fardsanei; M Arshadi; B Deihim; Farima Khalili; M Dadashi; M Goudarzi; M Mirsaeidi Journal: New Microbes New Infect Date: 2021-05-05